CDK Signaling in Oncology: Assess the Effectiveness of a CDK9-targeting PROTAC Molecule

CDK9 is an attractive target for cancer therapeutics due to its crucial role in transcription regulation, particularly of short-lived anti-apoptotic proteins such as MCL-1 and XIAP which are critical to the survival of cancer cells. One approach for specifically degrading CDK9 is using a proteolysis targeting chimera (PROTAC).

In this application note, you will discover:

• The rapid and strong effect of CDK9 PROTAC molecule Thal-SNS-032, demonstrating specificity in CDK9 degradation
• How HTRF^® and AlphaLISA^® SureFire^® Ultra^™ are used to measure protein levels, with each tool showcasing the ability of PROTACs to rapidly degrade a targeted protein making it a unique tool in the fight against cancer